Literature DB >> 18974297

Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice.

Michelle C Janelsins1, Michael A Mastrangelo, Keigan M Park, Kelly L Sudol, Wade C Narrow, Salvatore Oddo, Frank M LaFerla, Linda M Callahan, Howard J Federoff, William J Bowers.   

Abstract

Inflammatory mediators, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta, appear integral in initiating and/or propagating Alzheimer's disease (AD)-associated pathogenesis. We have previously observed a significant increase in the number of mRNA transcripts encoding the pro-inflammatory cytokine TNF-alpha, which correlated to regionally enhanced microglial activation in the brains of triple transgenic mice (3xTg-AD) before the onset of overt amyloid pathology. In this study, we reveal that neurons serve as significant sources of TNF-alpha in 3xTg-AD mice. To further define the role of neuronally derived TNF-alpha during early AD-like pathology, a recombinant adeno-associated virus vector expressing TNF-alpha was stereotactically delivered to 2-month-old 3xTg-AD mice and non-transgenic control mice to produce sustained focal cytokine expression. At 6 months of age, 3xTg-AD mice exhibited evidence of enhanced intracellular levels of amyloid-beta and hyperphosphorylated tau, as well as microglial activation. At 12 months of age, both TNF receptor II and Jun-related mRNA levels were significantly enhanced, and peripheral cell infiltration and neuronal death were observed in 3xTg-AD mice, but not in non-transgenic mice. These data indicate that a pathological interaction exists between TNF-alpha and the AD-related transgene products in the brains of 3xTg-AD mice. Results presented here suggest that chronic neuronal TNF-alpha expression promotes inflammation and, ultimately, neuronal cell death in this AD mouse model, advocating the development of TNF-alpha-specific agents to subvert AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18974297      PMCID: PMC2626388          DOI: 10.2353/ajpath.2008.080528

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observations.

Authors:  Michael R D'Andrea; Patti A Reiser; Deborah A Polkovitch; Norah A Gumula; Barbara Branchide; Brenda M Hertzog; Danielle Schmidheiser; Stanley Belkowski; Myriam C Gastard; Patricia Andrade-Gordon
Journal:  Neurosci Lett       Date:  2003-05-15       Impact factor: 3.046

2.  Molecular and cellular mediators of Alzheimer's disease inflammation.

Authors:  Ron Strohmeyer; Joseph Rogers
Journal:  J Alzheimers Dis       Date:  2001-02       Impact factor: 4.472

3.  Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice.

Authors:  Grace E Stutzmann; Ian Smith; Antonella Caccamo; Salvatore Oddo; Frank M Laferla; Ian Parker
Journal:  J Neurosci       Date:  2006-05-10       Impact factor: 6.167

4.  Purification with monoclonal antibody of a predominant leukocyte-common antigen and glycoprotein from rat thymocytes.

Authors:  C A Sunderland; W R McMaster; A F Williams
Journal:  Eur J Immunol       Date:  1979-02       Impact factor: 5.532

Review 5.  The role of microglia and macrophages in the pathophysiology of the CNS.

Authors:  G Stoll; S Jander
Journal:  Prog Neurobiol       Date:  1999-06       Impact factor: 11.685

6.  AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.

Authors:  D Sondhi; D A Peterson; E L Giannaris; C T Sanders; B S Mendez; B De; A B Rostkowski; B Blanchard; K Bjugstad; J R Sladek; D E Redmond; P L Leopold; S M Kaminsky; N R Hackett; R G Crystal
Journal:  Gene Ther       Date:  2005-11       Impact factor: 5.250

7.  Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice.

Authors:  Lauren M Billings; Salvatore Oddo; Kim N Green; James L McGaugh; Frank M LaFerla
Journal:  Neuron       Date:  2005-03-03       Impact factor: 17.173

8.  Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death.

Authors:  Rena Li; Libang Yang; Kristina Lindholm; Yoshihiro Konishi; Xu Yue; Harald Hampel; Dai Zhang; Yong Shen
Journal:  J Neurosci       Date:  2004-02-18       Impact factor: 6.167

9.  Glial fibrillary acidic protein and Alzheimer-type senile dementia.

Authors:  P E Duffy; M Rapport; L Graf
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

Review 10.  Microglia as a source and target of cytokines.

Authors:  Uwe-Karsten Hanisch
Journal:  Glia       Date:  2002-11       Impact factor: 8.073

View more
  105 in total

1.  A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease.

Authors:  Rashid Deane; Itender Singh; Abhay P Sagare; Robert D Bell; Nathan T Ross; Barbra LaRue; Rachal Love; Sheldon Perry; Nicole Paquette; Richard J Deane; Meenakshisundaram Thiyagarajan; Troy Zarcone; Gunter Fritz; Alan E Friedman; Benjamin L Miller; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

2.  Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients.

Authors:  Xin Cheng; Libang Yang; Ping He; Rena Li; Yong Shen
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response.

Authors:  David B Wang; Robert D Dayton; Richard M Zweig; Ronald L Klein
Journal:  Exp Neurol       Date:  2010-03-24       Impact factor: 5.330

4.  Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain.

Authors:  Sara L Montgomery; Michael A Mastrangelo; Diala Habib; Wade C Narrow; Sara A Knowlden; Terry W Wright; William J Bowers
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

Review 5.  Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.

Authors:  Kathryn A Frankola; Nigel H Greig; Weiming Luo; David Tweedie
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-05       Impact factor: 4.388

Review 6.  Innate immune activation in Alzheimer's disease.

Authors:  Ming-Ming Wang; Dan Miao; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

Review 7.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

Authors:  Boris Decourt; Debomoy K Lahiri; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

Review 8.  "Boomerang Neuropathology" of Late-Onset Alzheimer's Disease is Shrouded in Harmful "BDDS": Breathing, Diet, Drinking, and Sleep During Aging.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2015-04-25       Impact factor: 3.911

Review 9.  Inflammatory Cytokines and Alzheimer's Disease: A Review from the Perspective of Genetic Polymorphisms.

Authors:  Fan Su; Feng Bai; Zhijun Zhang
Journal:  Neurosci Bull       Date:  2016-08-27       Impact factor: 5.203

10.  The anti-inflammatory effect of melatonin on methamphetamine-induced proinflammatory mediators in human neuroblastoma dopamine SH-SY5Y cell lines.

Authors:  Kannika Permpoonputtana; Piyarat Govitrapong
Journal:  Neurotox Res       Date:  2012-08-18       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.